Bretylium

From Self-sufficiency
Jump to: navigation, search
Bretylium
File:Bretylium.svg
Systematic (IUPAC) name
N-(2-bromobenzyl)-N,N-dimethylethanaminium
Clinical data
Pregnancy
category
  • AU: C
  • US: C (Risk not ruled out)
Routes of
administration
IV, IM
Legal status
Legal status
Pharmacokinetic data
Bioavailability NA
Protein binding NA
Metabolism None
Biological half-life 7-8 hours
Excretion Renal
Identifiers
CAS Number 59-41-6
ATC code C01BD02 (WHO)
PubChem CID 2431
DrugBank APRD00830
ChemSpider 2337
Chemical data
Formula C11H17BrNScript error: No such module "String".
Molar mass 243.163 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Bretylium (also bretylium tosylate) is an antiarrhythmic agent.[1] It blocks the release of noradrenaline from nerve terminals. In effect, it decreases output from the peripheral sympathetic nervous system. The dose is 5-10 mg/kg and side effects are hypertension followed by hypotension and ventricular ectopy.

It was patented in 1978 by Marvin Bacaner at the University of Minnesota.[2]

Uses

It is used in emergency medicine, cardiology, & other specialties for the acute management of ventricular tachycardia & ventricular fibrillation. [3]

It is contraindicated in patients with AV (atrioventricular) heart block or digoxin toxicity.

Bretylium is only used in an ICU setting and should not be used elsewhere due to its dramatic actions and its predominant side effect of hypotension.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


de:Bretylium

es:Bretilio hr:Bretilij

it:Bretilio
  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. "University of Minnesota: Scholars Walk". Retrieved 2008-09-23. 
  3. "ACS". Retrieved 2008-09-23.